Cytotoxic amyloid and TAU proteins and end-organ dysfunction in extracorporeal life support
Active Grant Awarded Last action
- Award ID
- R01AG092881
- Recipient
-
Rhode Island Hospital UEI N876TLXYGCG4
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $616,875
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 4% complete
- Place of performance
- Providence, RI 02903, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Institute on Aging, within the Department of Health and Human Services, awarded Rhode Island Hospital (Lifespan division) Grant R01AG092881 on September 9, 2026, obligating $616,875 under Assistance Listing 93.866, Aging Research. The award funds a prospective observational cohort of veno-venous and veno-arterial ECMO patients from two centers. Investigators will collect repeated amyloid-beta (AB) and tau blood markers, neurophysiologic and neuroimaging data over the hospital course, and standardized evaluations of pulmonary, cardiac, renal, physical, and cognitive impairment, including protocolized brain MRI at hospital discharge and at three and six months after discharge. The work will also quantify AB and tau variants in the end-organs of deceased ECMO patients, paired with in vivo blood levels, and use established animal models to test whether circulating cytopathic AB and tau variants are sufficient to cause end-organ dysfunction. The period of performance ends July 31, 2031, and work is performed in Providence, Rhode Island 02903. The program supports biomedical, social, and behavioral research and research training on the aging process and the diseases of aging.
Description
- Abstract
- Extracorporeal membrane oxygenation (ECMO) has become a mainstay of support for patients suffering from refractory critical illness. Neurologic complications are the leading cause of death in the setting of ECMO. Limited studies have examined the prevalence and phenotypes of post-intensive care syndrome (PICS), neurocognitive and end-organ dysfunction after ECMO among survivors. Transmissible amyloid-beta (AΒ) and TAU variants are produced by the pulmonary endothelium in response to pneumonia and lung injury and circulating levels of AΒ and TAU can be isolated from ECMO oxygenators, especially among those with pneumonia, neurologic complications, and in non-survivors. In addition, levels of circulating AΒ and TAU during ECMO are associated with neurological complications, renal injury, cardiac function and death. We hypothesize that cytotoxic AΒ and TAU are produced as an evolutionarily conserved immunoprotective response to pulmonary pathogens and lung injury that circulate and cause acute and chronic sequelae in ECMO survivors when left unchecked. These end-organ impacts may be preventable, once we better understand these relationships in patients and experimental models. We will establish a prospective observational cohort of veno-venous and veno-arterial ECMO patients from two centers. We will collect repeated AΒ and TAU blood markers, neurophysiologic and neuroimaging data over the hospital course, and standardized evaluations for pulmonary, cardiac, renal, physical, and cognitive impairment and state-of-the-art protocolized brain magnetic resonance imaging at hospital discharge and three- and six-months after discharge. We will quantify AΒ/TAU variants in the end-organs of deceased ECMO patients, to be paired with blood levels in vivo. In our established animal models, we will determine whether circulating cytopathic AΒ and TAU variants are sufficient to cause end-organ injury. We will target amyloid precursor protein and test the effects of approved AΒ and TAU neutralizing immunotherapy in these experimental models. This comprehensive exploration of cytopathologic AΒ and TAU and their contributions to the most devastating and deadly ECMO complications will provide a rationale for therapeutic interventions to minimize long term health impacts in ECMO survivors.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $616,875 |
Quick answers
Who received award R01AG092881?
R01AG092881 was awarded to Rhode Island Hospital by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R01AG092881 worth?
$616,875 has been obligated on R01AG092881.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award